Clinical Trial Update: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating axitinib in combination with pembrolizumab in advanced alveolar soft part sarcoma and other soft tissue sarcomas has completed and post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Soft Tissue Sarcomas

Drugs mentioned

• INLYTA (AXITINIB)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Jonathan Trent, MD, PhD | Conditions: Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas | Phase 2 | Status: COMPLETED | Results posted: 2021-11-26